The anticonvulsant sulthiame maybe useful for the treatment of seizures in individuals with refractory epilepsy and learning disabilities, according to an open trial.
Researchers led by Matthias J. Koepp from the National Society of Epilepsy, Institute of Neurology, London, England, performed an uncontrolled open study on the efficacy and tolerability of sulthiame in patients with epilepsy and learning disability. Thirty six patients with both epilepsy and a learning disability took sulthiame for 14 weeks.
During this period, 22 of the patients achieved a greater than 50 percent reduction in their seizures, and three of these patients became seizure free. Twenty-six patients continued to take sulthiame for up to 120 weeks.
Of these patients, one remained seizure-free while five stopped taking the drug during the follow-up period.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!